InceptionR’s BioMarin Pharmaceuticals BMRN Stock Holding History

InceptionR’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,726	Closed	-$1.74M	–	667
2026 Q1	$1.74M	Buy	30,726 +13,048	+74%	+$761K	0.42%	37
2025 Q4	$1.05M	Sell	17,678 -8,111	-31%	-$442K	0.29%	92
2025 Q3	$1.4M	Sell	25,789 -10,816	-30%	-$619K	0.34%	63
2025 Q2	$2.01M	Buy	36,605 +30,021	+456%	+$1.77M	0.47%	23
2025 Q1	$465K	Sell	6,584 -27,435	-81%	-$1.85M	0.14%	291
2024 Q4	$2.24M	Buy	+34,019	New	+$2.28M	0.5%	14
2024 Q3	–	Sell	-8,421	Closed	-$693K	–	647
2024 Q2	$693K	Buy	+8,421	New	+$701K	0.2%	203
2024 Q1	–	Sell	-2,757	Closed	-$266K	–	590
2023 Q4	$266K	Buy	+2,757	New	+$244K	0.19%	251
2023 Q3	–	Sell	-5,113	Closed	-$443K	–	406
2023 Q2	$443K	Sell	5,113 -9,214	-64%	-$867K	0.24%	169
2023 Q1	$1.39M	Buy	14,327 +9,691	+209%	+$1M	0.45%	53
2022 Q4	$480K	Buy	+4,636	New	+$435K	0.25%	173

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

InceptionR's BMRN Position: Q2 2026 in Review

InceptionR sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 30,726 shares — an estimated $1.74M sold.

InceptionR first reported a position in BMRN in Q4 2022 and held it in 11 quarters. The position peaked at $2.24M in Q4 2024. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

InceptionR reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
InceptionR sold 30,726 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.74M.
InceptionR first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 11 quarters.
InceptionR's BioMarin Pharmaceuticals position peaked at $2.24M in Q4 2024.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on InceptionR's 13F filing for Q2 2026, filed 11 Aug 2026.